Search Results
Your search for c matches 3698 pages
Showing 3651 - 3698Circulating Inflammation Markers Associated With Risk of Lung Cancer
In a study reported in the Journal of the National Cancer Institute, Shiels et al identified 11 circulating inflammation markers significantly associated with lung cancer risk. A risk score using four of the markers distinguished risk levels among current and former smokers. Study Details This...
12-Gene Recurrence Score Independently Predicts Recurrence in Patients With Stage II/III Colon Cancer
In a study reported in Journal of Clinical Oncology, Greg Yothers, PhD, of the National Surgical Adjuvant Breast and Bowel Project (NSABP) Biostatistical Center and the University of Pittsburgh Graduate School of Public Health, and colleagues assessed performance of the 12-gene colon cancer...
Alternate VEGF Ligands Associated With Bevacizumab Resistance in Metastatic Colorectal Cancer
Results from a University of Colorado Cancer Center study indicated that bevacizumab (Avastin) resistance in patients with colorectal cancer may be due to increases in growth factors other than the targeted VEGF-A. The study, led by Christopher Lieu, MD, and published in the journal PLoS One,...
International Ki67 Reproducibility Study Shows High Intralaboratory but Only Moderate Interlaboratory Reproducibility
In a study reported in Journal of the National Cancer Institute, Mei-Yin C. Polley, PhD, of the National Cancer Institute, and colleagues assessed intralaboratory and interlaboratory variability in Ki67 scoring. They found high intralaboratory reproducibility but only moderate interlaboratory...
Surgical Management of Male Breast Cancer Differs Dramatically From That of Female Breast Cancer
In a study reported in the International Journal of Radiation Oncology Biology Physics, Emma C. Fields, MD, of the University of Colorado School of Medicine, and colleagues analyzed the stage-specific management of male breast cancer with surgery and radiation therapy and related them to outcomes...
Dasatinib Plus Docetaxel Does Not Improve Overall Survival in Men With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Data suggest that Src kinase-mediated interactions between prostate cancer cells and osteoclasts might promote bone metastasis and that the Src kinase inhibitor dasatinib (Sprycel) might exhibit synergy with docetaxel in prostate cancer. In a phase III trial (READY) reported in The Lancet Oncology, ...
Novel Agents Produce Encouraging Trends in Gastric Cancer
Several novel agents targeting the HER2, C-MET, and VEGF receptors have achieved encouraging results in gastric cancer, which is the second leading cause of cancer death worldwide. Charles Fuchs, MD, of Dana-Farber Cancer Institute, Boston, reviewed these new approaches in a presentation at the...
Most Gastroenterologists and Endoscopy Nurses Prefer Propofol Over Moderate Sedation in Screening Colonoscopies, but Would Pay Little Extra for It
Propofol is increasingly being used for sedation in screening colonoscopies in low-risk patients. In the United States, propofol can be administered only by an anesthesiologist, which can raise the cost of the procedure by $600 to $2,000. In a study reported in a research letter in JAMA Internal...
Computer-Aided Diagnosis Tool Might Help Distinguish Small Lung Cancer Nodules From Benign Nodules
The National Lung Screening Trial reported a 20% reduction in lung cancer mortality achieved through low-dose computed tomography (CT) screening of the at-risk population, compared to screening with chest x-ray. However, challenges with the clinical implication of CT screening for lung cancer...
Investigational Antibody-Drug Conjugate May Provide New Treatment Option for Pancreatic Cancer Patients
Patients with pancreatic cancer may benefit from an investigational member of an emerging class of anticancer drugs called antibody-drug conjugates, according to preclinical results presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held October...
Targeting Integrin β3-Src Pathway May Be Potential Strategy for Overcoming Anti-IGF-1R Antibody Resistance
Clinical trials have shown limited efficacy of anti–insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibodies, with the mechanisms of resistance to IGF-1R monoclonal antibody-based therapy remaining undefined. In preclinical studies reported in the Journal of the National...
Program Chairs Highlight Abstracts of Interest for the 2013 CTRC-AACR San Antonio Breast Cancer Symposium
The Program Chairs of the 2013 CTRC-AACR San Antonio Breast Cancer Symposium, which will be held December 10–14, 2013, have highlighted what they consider to be the most important abstracts to be presented at the Symposium. In a telebriefing in advance of the December meeting, C. Kent...
Patients With Poor Nutritional Status Before Radical Cystectomy Have a Higher Risk of Postoperative Complications
Patients with bladder cancer are two times more likely to have complications after a radical cystectomy procedure if they have a biomarker for poor nutritional status before the operation, according to study findings presented at the 2013 Clinical Congress of the American College of Surgeons....
ACOSOG Z1071 Trial Does Not Support Sentinel Lymph Node Surgery Following Neoadjuvant Chemotherapy for Node-Positive cN1 Breast Cancer
Sentinel lymph node surgery provides reliable nodal staging information and is associated with less morbidity than axillary lymph node dissection in patients with clinically node-negative breast cancer. The American College of Surgeons Oncology Group (ACOSOG) Z1071 (Alliance) trial examined the...
ASCO and the College of American Pathologists Issue Updated Guideline on HER2 Testing in Breast Cancer
ASCO and the College of American Pathologists (CAP) today issued a joint, updated guideline to improve the accuracy and reporting of human epidermal growth factor receptor 2 (HER2) testing in patients with invasive breast cancer. The six-recommendation guideline is based on a systematic review of...
Poorer Overall Survival With Sunitinib vs Sorafenib in Advanced Hepatocellular Cancer
In an open-label phase III superiority/noninferiority trial reported in Journal of Clinical Oncology by Ann-Lii Cheng, MD, of National Taiwan University Hospital in Taipei, sunitinib (Sutent) was associated with significantly poorer overall survival compared with sorafenib (Nexavar) in a population ...
ECC 2013: TP53 Status Predicts Benefit From Neoadjuvant Cetuximab in Rectal Cancer
In a retrospective analysis of the randomized phase II EXPERT-C trial presented at the European Cancer Congress 2013 (Abstract LBA7), TP53 emerged as a strong, independent predictive biomarker for the benefit of cetuximab (Erbitux) in high-risk, locally advanced rectal cancer, according to...
ECC 2013: Multiple Studies Validate Long-Term Survival Benefit of Ipilimumab in Melanoma
There is no longer any doubt that for the treatment of metastatic or locally advanced melanoma, ipilimumab (Yervoy) conveys long-term survival benefits, according to studies presented at the European Cancer Congress 2013. In the largest survival analysis of the CTLA-4 monoclonal antibody to date...
Increases in Melanoma Incidence and Mortality Unremitting Over 6 Decades, Study Finds
In a study reported in Journal of Clinical Oncology, Alan C. Geller, MPH, RN, of the Harvard School of Public Health, and colleagues assessed long-term trends in the incidence and mortality of melanoma in Connecticut, a state with complete and consistent tumor registration. They found...
Antiviral Treatment Improves Recurrence-Free and Overall Survival in HBV-Related Hepatocellular Carcinoma
Patients with hepatitis B virus (HBV)-related hepatocellular carcinoma have poor postoperative prognosis. In a study reported in Journal of Clinical Oncology, Jianhua Yin, MD, of the Second Military Medical University in Shanghai, and colleagues assessed the effects of nucleotide/nucleoside analog...
Test Could Identify Which Prostate Cancers Require Treatment
The level of expression of three genes associated with aging can be used to predict whether seemingly low-risk prostate cancer will remain slow-growing, according to researchers at the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center (CUMC). Use of this three-gene...
Versatile MicroRNAs Block Cancer Blood Supply, Suppress Metastasis
A family of microRNAs (miR-200) blocks cancer progression and metastasis by stifling a tumor’s ability to weave new blood vessels to support itself, researchers at The University of Texas MD Anderson Cancer Center reported in Nature Communications. Patients with lung, ovarian, kidney, or...
Breast Cancer Treatment in 10 Years: George Sledge, MD, Offers His Predictions
In a keynote lecture during the 2013 Breast Cancer Symposium breast cancer expert and ASCO Past President George Sledge, MD, offered five predictions for the future of the medical management of breast cancer. Dr. Sledge is now Chief of Oncology at Stanford University School of Medicine, Palo Alto,...
New Report Examines Trends in End-of-Life Care for Patients With Advanced Cancer
Although fewer Medicare patients with cancer died in the hospital in 2010 than in the years 2003–2007, aggressive treatment continues at the end of life, according to a new report from the Dartmouth Atlas Project. The findings also show that a significant number of patients were likely to...
Survival Trend With Palliative FOLFOX4 vs Doxorubicin in Asian Patients With Advanced Hepatocellular Carcinoma
In a study reported in Journal of Clinical Oncology, Shukui Qin, MD, of People’s Liberation Army Cancer Centre, Bayi Hospital, in Nanjing, and colleagues compared FOLFOX4 (infusional fluorouracil [5-FU], leucovorin, and oxaliplatin) with doxorubicin as palliative chemotherapy in patients with ...
No Overall Survival Benefit With Brivanib in Advanced Hepatocellular Carcinoma Patients After Sorafenib Failure or Intolerance
The investigational agent brivanib is a selective dual inhibitor of VEGF and fibroblast growth factor receptors, both implicated in hepatocellular carcinoma. In a trial (BRISK-PS) reported in Journal of Clinical Oncology, Josep M. Llovet, MD, of the Icahn School of Medicine at Mount Sinai in New...
First-Line Brivanib Not Noninferior to Sorafenib in Advanced Hepatocellular Carcinoma
The investigational drug brivanib is a dual inhibitor of VEGF and fibroblast growth factor signaling, both implicated in hepatocellular carcinoma. In a noninferiority trial (BRISK-FL) reported in Journal of Clinical Oncology, Philip J. Johnson, MD, of the Institute of Translational Medicine,...
Meta-Analysis Indicates BEACOPPescalated Is Superior in Advanced Hodgkin Lymphoma
Studies evaluating two standards of care in adults with advanced Hodgkin lymphoma—ie, increased-dose bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine (Matulane), and prednisone (BEACOPPescalated) and doxorubicin, bleomycin, vinblastine, and dacarbazine...
Researchers Identify Key Mechanism Behind Castration-Resistant Prostate Cancer
A team of researchers from UC Davis, UC San Diego, and other institutions has identified a key mechanism behind aggressive prostate cancer. Published online today in Nature, the study shows that two long noncoding RNAs, PRNCR1 and PCGEM1, activate androgen receptors, circumventing...
FDA Approves Dolutegravir to Treat HIV-1 Infection
The U.S. Food and Drug Administration (FDA) today approved dolutegravir (Tivicay), a new drug to treat HIV-1 infection. Dolutegravir is an oral integrase strand transfer inhibitor that interferes with one of the enzymes necessary for HIV to multiply. The drug is taken in combination with other...
Metformin Use Reduces All-Cause and Prostate Cancer–Specific Mortality in Men With Diabetes
In a study reported in Journal of Clinical Oncology, David Margel, MD, PhD, of University of Toronto, and colleagues examined the effect of duration of antidiabetic medication exposure after prostate cancer diagnosis on all-cause and prostate cancer–specific mortality in men with diabetes....
Study Reveals Best of Three Schedules of Nab-paclitaxel/Bevacizumab in Metastatic Breast Cancer
In a phase II study evaluating three dosing regimens of nanoparticle albumin-bound (nab)-paclitaxel (Abraxane) given with bevacizumab (Avastin), weekly dosing of nab-paclitaxel resulted in the highest overall response rate and longest progression-free survival. The schedule of nab-paclitaxel given...
Cancer Organizations Provide Support for Required Cancer Center Distress Screening Programs
The American Psychosocial Oncology Society (APOS) has announced recommendations to support a new criterion for cancer center accreditation. In 2015, the American College of Surgeons (ACoS) Commission on Cancer (CoC) will require cancer centers to implement screening programs for...
Soy Protein Supplementation Does Not Reduce Risk of Prostate Cancer Recurrence after Radical Prostatectomy
Among men who had undergone radical prostatectomy, daily consumption of a beverage powder supplement containing soy protein isolate for 2 years did not reduce or delay development of biochemical recurrence of prostate cancer compared to men who received placebo, according to a study in the July 10...
Novel Research Method May Lead to Tailored Treatments for Late-stage Prostate Cancer
A study using a novel “co-clinical” approach that integrates data from hundreds of genetically engineered mouse models with clinical data from tissue samples of hundreds of patients with castration-resistant prostate cancer, has identified several molecular pathways underlying...
High Rate of Durable Remissions with BTK Inhibitor Ibrutinib in Patients with Relapsed Chronic Lymphocytic Leukemia
Durable remissions are uncommon with current treatments for relapsed chronic lymphocytic leukemia (CLL). Bruton’s tyrosine kinase (BTK) is an essential component of B-cell receptor signaling that mediates interactions with the tumor microenvironment and promotes survival and proliferation of...
ASCO 2013: Lung Cancer Mutations ALK and ROS1 Also Drive Colorectal Cancer
A study from the University of Colorado Cancer Center shows that the ALK and ROS1 gene rearrangements known to drive subsets of lung cancer are also present in some colorectal cancers. Results imply that drugs used to target ALK and ROS1 in lung cancer may also have applications in this subset of...
FDA Approves Low-dose, Two-dimensional Mammography Software
Hologic, Inc, announced today that the U.S. Food and Drug Administration (FDA) has approved the use of C-View, a new low-dose two-dimensional (2D) imaging software. C-View 2D images may now be used in place of the conventional 2D exposure previously required as part of Hologic’s FDA-approved...
Bladder Cancer Could Recur despite Bladder Removal
Patients with advanced bladder cancers that are surgically removed might need additional therapy to prevent recurrence in certain situations, a new UT Southwestern Medical Center study suggests. The 5-year international study led by researchers at UT Southwestern validates the use of a marker...
Researchers Identify New Pathway, Enhancing Tamoxifen to Tame Aggressive Breast Cancer
Tamoxifen is a time-honored breast cancer drug used to treat millions of women with early-stage and less-aggressive disease, and now a University of Rochester Medical Center (URMC) team has shown how to exploit tamoxifen’s secondary activities so that it might work on more aggressive breast...
Pathologists Identify Patterns of Mutations to Help Inform Design of Future Trials
Molecular driven therapeutic targets have resulted in a paradigm shift in the treatment of advanced lung adenocarcinoma. However, in early non–small cell lung cancer (NSCLC), surgical resection remains the treatment of choice with adjuvant chemotherapy. In a recent study published in the...
Cervical Cancer Patients More Likely to Survive if Treated at High-volume Medical Facilities
Patients with locally advanced cervical cancer have better treatment outcomes and are more likely to survive the disease if they receive care at a high-volume medical center than patients treated at low-volume facilities, according to research presented at the Society of Gynecologic...
Study Shows Confidence Builds Better Exercise Habits for Cancer Survivors
Endometrial cancer survivors are more likely to complete physical activity, and for longer durations, when their daily self-efficacy is higher, according to a study published online in the journal Health Psychology, a publication of the American Psychology Association. “Sedentary behavior is ...
Tackling Tobacco Consumption and Improving Vaccination Access Are Two of the Best Ways to Reduce Global Cancer Burden
Combatting the tobacco industry’s tactics in the world’s poorest countries as well as ensuring the best cancer vaccines are available to those most in need are key in order to reduce the number of cancer deaths worldwide, according to a new report published in the journal Science...
Breast Cancer Patients’ Fear of Developing Lymphedema Far Exceeds Risk
Women who have had the lymph nodes under their arm surgically removed during breast cancer treatment are warned to avoid certain practices that can cause lymphedema. Now, a new study published in the March issue of the Journal of the American College of Surgeons suggests that the vast majority of...
Inaugural Winners of the Breakthrough Prize in Life Sciences Announced
Founding sponsors Art Levinson, PhD, Sergey Brin, Anne Wojcicki, Mark Zuckerberg, Priscilla Chan, and Yuri Milner announced the launch of the Breakthrough Prize in Life Sciences, recognizing excellence in research aimed at curing intractable diseases and extending human life. The prize will be...
NCI Researchers Identify Molecular Link between Metabolism and Breast Cancer
A protein associated with conditions of metabolic imbalance, such as diabetes and obesity, may play a role in the development of aggressive forms of breast cancer, according to new findings by researchers at the National Cancer Institute (NCI), part of the National Institutes of Health, and their...
Alex’s Lemonade Stand Foundation Introduces Centers of Excellence Program to Further Childhood Cancer Research
Alex’s Lemonade Stand Foundation (ALSF), a registered 501(c)(3) charity, is furthering its commitment to finding cures for all children with cancer by introducing the ALSF Centers of Excellence program. The Centers of Excellence program aims to fund the research of leading childhood cancer...
